Recent studies have found that PRELP could affect tumor immunogenicity in melanoma by up-regulating MHC Class I surface expression, thereby inhibiting tumor development and enhancing CD8 T cell infiltration (34), which was consistent with our findings. This evidence concerns the gene CD8A and melanoma.